Local News

• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• Medtronic announces clinical trial of stent for peripheral arterial disease  Consistent with its commitment to addressing unmet patient needs, Medtronic announced the first enrollment in the company's FDA-approved clinical trial of its self-expanding (SE) Complete SE stent for the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA).
  Medtronic, Inc. January 05, 2009  
• Medtronic launches its first Integrated Power Console Platform for use in spinal surgeries  Medtronic announced the launch of the Integrated Power Console (IPC(TM)) platform, its first multispecialty surgical power console for use in spinal, cranial, and ear, nose, and throat (ENT) surgeries.
  Medtronic, Inc. January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Grand Rapids looks to diversify into health care, life sciences  In a state grasping for answers about its future, Michigan's second-largest city may provide some important clues. Along a hilly stretch of downtown Grand Rapids dubbed the Medical Mile, a new economic engine is gradually taking shape.
  Detroit Free Press January 04, 2009  Katherine Yung
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
  Johnson & Johnson December 30, 2008  
• Celera and Abbott revise strategic alliance  Celera and Abbott announced a revision of the strategic alliance agreement between the two companies. Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera.
  Celera Corporation December 29, 2008  
• Johnson & Johnson completes tender offer for Omrix Biopharmaceuticals  Johnson & Johnson announced that stockholders of Omrix Biopharmaceuticals tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock.
  Johnson & Johnson December 27, 2008  
• Mayo-connected biotech firm prepares treatments for studies  A biotech firm using Mayo Clinic created technology is hoping a new nano material will hit a big $35.5 billion market to aid wound healing, treating diabetic, fight cancer and even grow hair.
  Post-Bulletin (Rochester, MN) December 24, 2008  Jeff Kiger

   (next 10 articles)